COVID-19

Vaccinations in multiple sclerosis patients receiving disease-modifying drugs

Is the Frontal Lobe the Primary Target of SARS-CoV-2 ?

Acute ischemic stroke in patients with COVID-19: an analysis from Get With The Guidelines-Stroke

Seroprevalence of SARS-CoV-2 in Parkinson’s disease patients: a case-control study

Brainstem clinical and neurophysiological involvement in COVID-19

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques

Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein

The first 12 months of COVID-19: a timeline of immunological insights

The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue

A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies